Thomas Goebel

Thomas joined NeoMed in 2005. He manages NeoMed’s funds and assists with and advises on new investments for Omega.

Thomas has over 10 years of experience of venture capital investing in healthcare in Europe. Previously, he was a global biotechnology analyst for Pictet & Cie, Switzerland’s largest private bank. He was also Manager of Regulatory Affairs with worldwide responsibilities at Firmenich SA, a global leader in fragrances, flavourings and fine chemicals. Thomas holds a PhD in molecular biology from the University of Geneva, Switzerland.